- Scott Kappes | August 21, 2008 5:36 PM | Houston, TX
Category:
FDA & Prescription Drugs
Last week 10 former and current editors and authors of the prestigious
New England Journal of Medicine showed exactly how they feel about the issue of
preemption by filing a brief in the Supreme...
- Scott Kappes | July 03, 2008 4:45 PM | Houston, TX
Category:
FDA & Prescription Drugs
Preemption has been a hot topic throughout the
pharmaceutical and legal fields for some time now and as we move closer to
monumental decision from the Supreme Court on the issue it has become...
- Scott Kappes | May 15, 2008 12:25 PM | Houston, TX
Category:
FDA & Prescription Drugs
Yesterday the FDA announced that Bayer would be removing
remaining stocks of Trasylol after a study confirming suspected increased death
risks was published in the New England Journal of...
- Scott Kappes | May 15, 2008 11:12 AM | Galveston Bay, TX
Category:
FDA & Prescription Drugs
The results of a study published in the New England Journal of Medicine have confirmed preliminary findings that Bayer’s anti-bleeding
medication Trasylol (aprotinin) dramatically increases a...
- Robert Binstock | May 14, 2008 6:52 PM | Houston, TX
Category:
FDA & Prescription Drugs
According to a long awaited study published today, Bayer’s
Trasylol has a 53 percent higher death rate than other similar drugs. Trasylol
was withdrawn from the market in November after the...
- Robert Binstock | May 05, 2008 3:55 PM | Galveston Bay, TX
Category:
FDA & Prescription Drugs
A new lawsuit has been filed against Bayer in response to
the controversy currently surrounding Trasylol. This lawsuit however does not
make a personal injury claim against the company, as...